# US 2022/0033519 A1 · Intrabodies for reducing fut8 activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033519 A1
- Document ID: US20220033519A1
- Status: Published application
- Kind: A1
- Application number: 17/278,509
- Filed: 2019-09-20
- Published: 2022-02-03
- Earliest claimed: 2018-09-21
- Assignees: National Research Council of Canada
- Applicants: National Research Council of Canada
- Inventors: Yves DUROCHER; Simon JOUBERT
- Web page: https://patentgrep.com/patent/US20220033519A1

## CPC

- C07K 16/40: against enzymes
- C12N 15/62: DNA sequences coding for fusion proteins
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/03: containing a transmembrane segment
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present document describes an alpha-(1,6)-fucosyltransferase (FUT8) antibody, antigen binding domain thereof, or a fusion protein thereof, operable to inhibit FUT8 activity in a cell, and methods of producing recombinant proteins, in particular antibodies, having reduced fucosylation. The present document also describes methods of inhibiting expression and/or activity of a protein in a cell by expressing an antibody and/or a fusion protein operable to inhibit expression and/or activity of the protein. The antibody, antigen binding domain thereof, or fusion protein thereof may comprise a transmembrane domain of a protein resident in an endoplasmic reticulum (ER), a cis Golgi apparatus, a trans Golgi apparatus, or a combination thereof.

## Claims

### Claim 1

An alpha-(1,6)-fucosyltransferase (FUT8) antibody, an antigen binding domain thereof, or a fusion protein thereof, comprising a variable region of a heavy (VH) and a light (VL) chain thereof, the antibody or antigen binding domain thereof, or fusion protein thereof being operable to inhibit FUT8 activity in a cell.

### Claim 2 (depends on 1)

The FUT8 antibody, antigen binding domain thereof, or fusion protein thereof of claim 1, wherein said fusion protein comprises a transmembrane domain of a protein resident in an endoplasmic reticulum (ER), a cis Golgi apparatus, a trans Golgi apparatus, or a combination thereof.

### Claim 3 (depends on 1)

A cell expressing the FUT8 antibody, antigen binding domain thereof or fusion protein thereof of claim 1.

### Claim 4 (depends on 1)

A method for producing a recombinant protein or antibody having reduced fucosylation comprising:
a) culturing a host cell expressing a FUT8 antibody, antigen binding domain thereof or fusion protein thereof of claim 1,
wherein said host cell expresses said recombinant protein or antibody under conditions which permit the production of said recombinant protein or antibody; and
b) isolating said recombinant protein or antibody.

### Claim at position 5

-7. (canceled)

### Claim 8 (depends on 1)

A FUT8 antibody, an antigen binding domain thereof, or a fusion protein thereof comprising a variable region of a heavy (VH) and a light (VL) chain thereof according to claim 1, wherein said variable region heavy (VH) chain comprises an amino acid sequence comprising SEQ ID NO:1, and said variable region light (VL) chain comprises an amino acid sequence comprising SEQ ID NO:2.

### Claim 9 (depends on 1)

A FUT8 antibody, an antigen binding domain thereof or a fusion protein thereof comprising a variable region of a heavy (VH) and a light (VL) chain thereof according to claim 1,
wherein said variable region heavy (VH) chain comprises CDR 1, CDR2 and CDR3 comprising an amino acid sequence comprising SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, respectively;
and wherein said variable region light (VL) chain comprises CDR 1, CDR2 and CDR3 comprising an amino acid sequence comprising SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, respectively.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A FUT8 antibody, an antigen binding domain thereof, or a fusion protein thereof comprising a variable region of a heavy (VH) and a light (VL) chain thereof according to claim 1, wherein said variable region heavy (VH) chain comprises an amino acid sequence comprising SEQ ID NO:9, and said variable region light (VL) chain comprises an amino acid sequence comprising SEQ ID NO:10.

### Claim 12 (depends on 1)

A FUT8 antibody, an antigen binding domain thereof, or a fusion protein thereof comprising a variable region of a heavy (VH) and a light (VL) chain thereof according to claim 1,
wherein said variable region heavy (VH) chain comprises CDR 1, CDR2 and CDR3 comprising an amino acid sequence comprising SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively;
and wherein said variable region light (VL) chain comprises CDR 1, CDR2 and CDR3 comprising an amino acid sequence comprising SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16, respectively.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A FUT8 antibody, an antigen binding domain thereof, or a fusion protein thereof comprising a variable region of a heavy (VH) and a light (VL) chain thereof according to claim 1, wherein said variable region heavy (VH) chain comprises an amino acid sequence comprising SEQ ID NO:17, and said variable region light (VL) chain comprises an amino acid sequence comprising SEQ ID NO:18.

### Claim 15 (depends on 1)

A FUT8 antibody, an antigen binding domain thereof, or a fusion protein thereof comprising a variable region of a heavy (VH) and a light (VL) chain thereof according to claim 1,
wherein said variable region heavy (VH) chain comprises CDR 1, CDR2 and CDR3 comprising an amino acid sequence comprising SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21, respectively;
and wherein said variable region light (VL) chain comprises CDR 1, CDR2 and CDR3 comprising an amino acid sequence comprising SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24, respectively.

### Claim at position 14

-17. (canceled)

### Claim 18 (depends on 1)

The FUT8 antibody, antigen binding domain thereof, or fusion protein thereof of claim 1, wherein said FUT8 antibody or a fusion protein thereof further comprises an endoplasmic reticulum retention signal.

### Claim 19 (depends on 1)

The FUT8 antibody, antigen binding domain thereof, or fusion protein thereof of claim 1, wherein said FUT8 antibody, antigen binding domain, or fusion protein is an IgA, IgD, IgE, IgM, Fab, scFv, scFab, sdAb, any antigen binding protein, or any combination thereof.

### Claim 20 (depends on 4)

The method of claim 4, wherein said fusion protein is a scFv.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The FUT8 antibody, antigen binding domain thereof, or fusion protein thereof of claim 1, wherein said transmembrane domain is chosen from a transmembrane domain of FUT8, a transmembrane domain of beta-1,4-galactosyltransferase 1 (B4GT1), and a transmembrane domain of human calnexin (hCNX).

### Claim 23 (depends on 22)

The FUT8 antibody, antigen binding domain thereof, or fusion protein thereof, of claim 22, wherein said transmembrane domain of FUT8 is comprising an amino acid sequence comprising SEQ ID NO:25, said transmembrane domain of B4GT1 is comprising an amino acid sequence comprising SEQ ID NO:26, and said transmembrane domain of hCNX is comprising an amino acid sequence comprising SEQ ID NO:27.

### Claim 24 (depends on 18)

The FUT8 antibody, antigen binding domain thereof, or fusion protein thereof, of claim 18, wherein said endoplasmic reticulum retention signal is comprising an amino acid sequence comprising SEQ ID NO:28.
